title: Letter to the editor concerning the paper: Boltjes A, Op den Brouw ML, Biesta PJ, et al. Assessment of the effect of ribavirin on myeloid and plasmacytoid dendritic cells during interferon-based therapy of chronic hepatitis B patients [Molecular Immunology 53(1/2) (2013) 72-78].
authors.forename: Ioannis
authors.initials: I
authors.lastname: Pachiadakis
authors.forename: Shilpa
authors.initials: S
authors.lastname: Choksi
authors.forename: Georgios
authors.initials: G
authors.lastname: Ilonidis
authors.forename: Evangelos
authors.initials: E
authors.lastname: Akriviadis
authors.forename: Ioannis
authors.initials: I
authors.lastname: Goulis
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage*; D003713:Dendritic Cells / Q000187:drug effects*; D005260:Female; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage*; D008297:Male; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D012254:Ribavirin / Q000008:administration & dosage*
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D011092:Polyethylene Glycols; D012254:Ribavirin